磁共振成像-质子密度脂肪分数与非酒精性脂肪性肝病或非酒精性脂肪性肝炎患者肝脏组织学特征之间的关联
本研究回顾性汇总3项2a期药物试验数据,分析370例非酒精性脂肪性肝病或非酒精性脂肪性肝炎患者基线MRI-PDFF与肝组织学特征的关系。结果显示PDFF与脂肪变分级、NAFLD活动度评分(NAS)正相关,与纤维化分期负相关,但识别NAS≥4或纤维化分期≥3的准确性欠佳。结论认为肝活检分析仍属必要。
要点
- 在370例患者中,基线PDFF均值17.4%±8.6%。
- PDFF与脂肪变分级(r=0.78)、NAS(r=0.54)正相关,与纤维化分期负相关(r=-0.59)。
- PDFF识别NAS≥4的AUROC为0.72,识别纤维化分期≥3的AUROC为0.66,准确性欠佳。
核心结论
- 在非酒精性脂肪性肝病或非酒精性脂肪性肝炎患者中,MRI-PDFF与脂肪变分级和NAS相关、与纤维化分期呈负相关,但识别NAS≥4或晚期纤维化的能力欠佳;MRI-PDFF是继续评估该人群的重要影像生物标志物,但肝活检分析仍属必要。
研究设计与样本
- 回顾性分析,汇总3项针对非酒精性脂肪性肝病或非酒精性脂肪性肝炎的2a期药物试验数据,纳入其中1项试验内接受MRI分析的全部受试者,收集基线临床、实验室和肝组织病理学资料,共370例。
- 采用相关分析和受试者工作特征曲线下面积(AUROC)分析评估肝脏PDFF值与肝组织学表现的关系。
- 作为辅助分析,模拟临床试验筛选流程,计算PDFF入选阈值6%至15%所致的受试者排除率及人群特征差异。
主要发现
- 在370例受试者中,基线PDFF均值为17.4%±8.6%。
- 基线PDFF值与脂肪变分级相关(r=0.78;P<.001),与NAFLD活动度评分(NAS)相关(r=0.54;P<.001),与纤维化分期呈负相关(r=-0.59;P<.001)。
- PDFF未能准确识别NAS≥4的患者(AUROC=0.72)或纤维化分期≥3的患者(AUROC=0.66)。
- 在理论试验中,排除率随PDFF最低阈值水平升高而增加;采用6%至15%的PDFF阈值时,队列人口学特征无显著差异,实验室和肝组织病理学数据的差异较小。
关键数值与推荐
- 基线PDFF与脂肪变分级:r=0.78;P<.001。
- 基线PDFF与NAFLD活动度评分(NAS):r=0.54;P<.001。
- 基线PDFF与纤维化分期:r=-0.59;P<.001。
- PDFF识别NAS≥4的AUROC=0.72;识别纤维化分期≥3的AUROC=0.66。
- PDFF入选阈值6%至15%时,排除率随阈值升高而增加,队列人口学特征无显著差异,实验室和肝组织病理学数据差异较小。
临床怎么用
- 作者认为,MRI-PDFF是继续评估该患者人群的重要影像生物标志物,但肝活检分析仍属必要。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Patients with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH) often require histologic assessment via liver biopsy. Magnetic resonance imaging (MRI)-based methods for measuring liver triglycerides based on proton density fat fraction (PDFF) are increasingly used as a noninvasive tool to identify patients with hepatic steatosis and to assess for change in liver fat over time. We aimed to determine whether MRI-PDFF accurately reflects a variety of liver histology features in patients with NAFLD or NASH. METHODS: We performed a retrospective analysis of pooled data from 3 phase 2a trials of pharmacotherapies for NAFLD or NASH. We collected baseline clinical, laboratory, and histopathology data on all subjects who had undergone MRI analysis in 1 of the trials. We assessed the relationship between liver PDFF values and liver histologic findings using correlation and area under the receiver operating characteristic (AUROC) analyses. As an ancillary analysis, we also simulated a clinical trial selection process and calculated subject exclusion rates and differences in population characteristics caused by PDFF inclusion thresholds of 6% to 15%. RESULTS: In 370 subjects, the mean baseline PDFF was 17.4% ± 8.6%. Baseline PDFF values correlated with several histopathology parameters, including steatosis grade (r = 0.78; P < .001), NAFLD activity score (NAS, r = 0.54; P < .001), and fibrosis stage (r = -0.59; P < .001). However, PDFF did not accurately identify patients with NAS ≥ 4 (AUROC = 0.72) or fibrosis stage ≥3 (AUROC = 0.66). In a theoretical trial of these subjects, exclusion rates increased as PDFF minimum threshold level increased. There were no significant differences in cohort demographics when PDFF thresholds ranging from 6% to 15% were used, and differences in laboratory and histopathology data were small. CONCLUSIONS: In an analysis of patients with NAFLD or NASH, we determined that although The MRI-PDFF correlated with steatosis grade and NAS, and inversely with fibrosis stage, it was suboptimal in identification of patients with NAS >4 or advanced fibrosis. Although MRI-PDFF is an important imaging biomarker for continued evaluation of this patient population, liver biopsy analysis is still necessary.
引用
- Wildman-Tobriner B, Middleton MM, Moylan CA, et al. Association Between Magnetic Resonance Imaging-Proton Density Fat Fraction and Liver Histology Features in Patients With Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis. Gastroenterology. 2018. PMID: 30031769. doi:10.1053/j.gastro.2018.07.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。